Richard Lam, MD

Curriculum Vitae [ CV ]

A double board-certified internist and oncologist, Richard Lam, MD, has been specializing full time at Prostate Oncology Specialists in the treatment of prostate cancer since 2001. He is our director of clinical research.

Dr. Lam has written numerous articles based on his research. He is an active member of the American Society of Clinical Oncology and the American Society of Hematology. Dr. Lam continues to promote prostate cancer awareness and education by giving lectures at various medical conferences and prostate support groups throughout the country. He is particularly interested in utilizing state-of-the-art therapeutics for advanced prostate cancer.

Dr. Lam received his undergraduate degree in biology, magna cum laude, at UCLA. He then went on to earn his medical degree at UCLA School of Medicine before completing his residency training in the specialty of internal medicine at UCLA Center of Health Sciences. He completed his oncology and hematology fellowship at Harbor-UCLA Medical Center.

GU 115/I6A-MC-CBBD: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer.

Lack of Benefit of Local Therapy for Men with Preexisting AIPC.

OGX-011-11: A Randomized Phase III Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custersin (OGX-011) in Men with Metastatic Castrate-Resistant Prostate Cancer.

P11-4 PRIME: Immune Monitoring Protocol in Men with Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T.

P12-1: A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients with Castration-Resistant Prostate Cancer.

Prevention of Gynecomastia with an Aromatase Inhibitor Femara.

PROCEDE-1000: An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients
Prognostic Significance of Negative Biopsy after 12 Months of Hormone Blockade.

SIPIPI 2013: Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer
Testosterone Replacement for Hypogonadal Men with Treated Prostate Cancer.
The Effect of Finesteride on Prolonging Time off in Patients on Intermittent Hormone Blockade
The Prevention of Bone Loss with Oral Bisphosphonates.